Novo Nordisk A/S (NONOF)
127.72
+0.72
(+0.56%)
USD |
OTCM |
May 09, 16:00
Novo Nordisk Cash from Investing (TTM): -4.987B for June 30, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
June 30, 2023 | -4.987B |
March 31, 2023 | -4.203B |
December 31, 2022 | -3.532B |
September 30, 2022 | -4.783B |
June 30, 2022 | -4.871B |
March 31, 2022 | -4.752B |
December 31, 2021 | -5.029B |
September 30, 2021 | -3.684B |
June 30, 2021 | -3.957B |
March 31, 2021 | -3.691B |
December 31, 2020 | -3.438B |
September 30, 2020 | -1.987B |
June 30, 2020 | -1.357B |
March 31, 2020 | -1.576B |
December 31, 2019 | -1.726B |
September 30, 2019 | -1.905B |
June 30, 2019 | -1.975B |
March 31, 2019 | -1.949B |
December 31, 2018 | -1.914B |
September 30, 2018 | -1.706B |
June 30, 2018 | -1.611B |
March 31, 2018 | -1.326B |
December 31, 2017 | -1.000B |
September 30, 2017 | -939.19M |
June 30, 2017 | -1.009B |
Date | Value |
---|---|
March 31, 2017 | -870.94M |
December 31, 2016 | -1.009B |
September 30, 2016 | -1.307B |
June 30, 2016 | -1.398B |
March 31, 2016 | -1.424B |
December 31, 2015 | -907.22M |
September 30, 2015 | -490.48M |
June 30, 2015 | -187.47M |
March 31, 2015 | -165.51M |
December 31, 2014 | -368.14M |
September 30, 2014 | -180.14M |
June 30, 2014 | -348.92M |
March 31, 2014 | -347.84M |
December 31, 2013 | -493.76M |
September 30, 2013 | -691.26M |
June 30, 2013 | -630.28M |
March 31, 2013 | -534.54M |
December 31, 2012 | -702.86M |
September 30, 2012 | -882.14M |
June 30, 2012 | -700.34M |
March 31, 2012 | -864.76M |
December 31, 2011 | -646.16M |
September 30, 2011 | -827.89M |
June 30, 2011 | -867.50M |
March 31, 2011 | -952.61M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-5.029B
Minimum
Dec 2021
-1.357B
Maximum
Jun 2020
-3.380B
Average
-3.684B
Median
Sep 2021
Cash from Investing (TTM) Benchmarks
Eli Lilly and Co | -7.642B |
Amgen Inc | -27.78B |
Genmab A/S | -394.15M |
Ascendis Pharma A/S | 91.67M |